Beyond rituximab: The future of monoclonal antibodies in B-cell non-Hodgkin lymphoma

Current Hematologic Malignancy Reports

Volumn 3, Issue 4, 2008, Pages 187-193

  Sikder, Manzurul A ^b   Friedberg, Jonathan W ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ANTINEOPLASTIC AGENT; B7 ANTIGEN; CD20 ANTIBODY; CD40 ANTIGEN; CD52 ANTIGEN; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPRATUZUMAB; FC RECEPTOR; FC RECEPTOR IIIA; GALIXIMAB; INOTUZUMAB OZOGAMICIN; MONOCLONAL ANTIBODY; OCRELIZUMAB; OFATUMUMAB; PREDNISONE; PRO 131921; RECOMBINANT HUMAN MONOCLONAL ANTIBODY V114; RITUXIMAB; SGN 40; UNCLASSIFIED DRUG; VELTUZUMAB; VINCRISTINE;

B CELL LYMPHOMA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER RELAPSE; CANCER SURVIVAL; CHILL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CYTOMEGALOVIRUS INFECTION; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG TREATMENT FAILURE; FATIGUE; HUMAN; INFECTION; INJECTION SITE REACTION; LYMPHOMA; MONOTHERAPY; MYALGIA; NONHODGKIN LYMPHOMA; RECOMMENDED DRUG DOSE; REVIEW; STEM CELL TRANSPLANTATION; SYSTEMIC LUPUS ERYTHEMATOSUS; UNSPECIFIED SIDE EFFECT; VIREMIA;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; LYMPHOMA, B-CELL;

EID: 59249106395     PISSN: 15588211     EISSN: 1558822X     Source Type: Journal    
DOI: 10.1007/s11899-008-0027-5     Document Type: Review

References (37)

1. Köhler G, Milstein C: Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975, 256:495-497.
2. Miller RA, Maloney DG, Warnke R, Levy R: Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. N Engl J Med 1982, 306:517-522.
3. Foon KA, Schroff RW, Bunn PA, et al.: Effects of monoclonal antibody therapy in patients with chronic lymphocytic leukemia. Blood 1984, 64:1085-1093.
4. Jemal A, Siegel R, Ward E, et al.: Cancer statistics 2006. CA Cancer J Clin 2006, 56:106-130.
5. Fisher RI, LeBlanc M, Press OW, et al.: New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol 2005, 23:8447-8452.
6. Swenson WT, Wooldridge JE, Lynch CF, et al.: Improved survival of follicular lymphoma patients in the United States. J Clin Oncol 2005, 23:5019-5026.
7. Feugier P, van Hoof A, Sebban C, et al.: Long term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: A study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2005, 23:4117-4126.
8. Pfreunschuh M, Trumper L, Osterborg A, et al.: CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: A randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006, 7:379-391.
9. McLaughlin P, Grillolopez AJ, Link BK, et al.: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998, 16:2825-2833.
10. Hainsworth JD, Litchy S, Burris HA, et al.: Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma. J Clin Oncol 2002, 20:4261-4267.
11. Davis TA, Grillo-Lopez AJ, White CA, et al.: Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: Safety and efficacy of re-treatment. J Clin Oncol 2000, 18:3135-3143.
12. Friedberg JW: Unique toxicities and resistance mechanisms associated with monoclonal antibody therapy. Hematology Am Soc Hematol Educ Program 2005, 329-334.
13. Smith MR: Rituximab (monoclonal anti-MD20 antibody): mechanisms of action and resistance. Oncogene 2003, 22:7359-7368.
14. Bohen SP, Troyanskaya OG, Alter O, et al.: Variation in gene expression patterns in follicular lymphoma and the response to rituximab. Proc Natl Acad Sci U S A 2003, 100:1926-1930.
15. Morschhauser F, Leonard JP, Coiffier B, et al.: Initial safety and efficacy results of a second-generation humanized anti-CD20 antibody, IMMU-106 (hA20), in non-Hodgkin's lymphoma [abstract 2428]. Blood 2005, 106:683a.
16. Teeling JL, French RR, Cragg MS, et al.: Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood 2004, 104:1793-1800.
17. Coiffier B, Lepretre S, Pederen LM, et al.: Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia. A phase I-II study. Blood 2008, 111:1094-1100.
18. Morschhauser F, Marlton P, Vitolo U, et al.: Interim results of a phase I/II study of ocrelizumab, a new humanized anti-CD20 antibody in patients with relapsed/refractory follicular non-Hodgkin's lymphoma [abstract 645]. Blood 2007, 110:199a.
19. Shields RL, Namenuk AK, Hong K, et al.: High resolution mapping of the binding site on human IgG1 for FcgammaR1, FcgammaRII, FcgammaRIII, and FcRn and design of IgG1 variants with improved binding to the FcR. J Biol Chem 2001, 276:6591-6604.
20. Idusogie EE, Presta LG, Gazzano-Santoro H, et al.: Mapping of the C1q binding site on Rituxan, a chimeric antibody with human IgG1 Fc. J Immunol 2000, 164:4178-4184.
21. Sato S, Tuscano JM, Inaoki M, et al.: CD22 negatively and positively regulates signal transduction through the B lymphocyte antigen receptor. Semin Immunol 1998, 10:287-297.
22. Dörner T, Kaufmann J, Wegener WA, et al.: Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res Ther 2006, 8:R4.
23. Leonard JP, Coleman M, Ketas JC, et al.: Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma. J Clin Oncol 2003, 21:3051-3059.
24. Leonard JP, Coleman M, Ketas JC, et al.: Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: Phase I/II clinical trial results. Clin Cancer Res 2004, 10:5327-5334.
25. Leonard JP, Coleman M, Ketas J, et al.: Combination anti-body therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma. J Clin Oncol 2005, 23:5044-5051.
26. Stein R, Qu Zhengzing, Chen S, et al.: Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma. Clin Cancer Res 2004, 10:2868-2878.
27. DiJoseph JF, Dougher MM, Kalyandrug LB, et al.: Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin's B-cell lymphoma. Clin Cancer Res 2006, 12:242-249.
28. Postema EJ, Raemaekers JM, Oyen WJ, et al.: Final results of a phase I radioimmunotherapy trial using 186Re-epratuzumab for the treatment of patients with non-Hodgkin's lymphoma. Clin Cancer Res 2003, 9:3995S-4002S.
29. Law CL, Gordon KA, Collier J, et al.: Preclinical antilymphoma activity of a humanized anti-CD40 monoclonal antibody, SGN-40. Cancer Res 2005, 65:8331-8338.
30. Advani RH, Furman RR, Rosenblatt JD, et al.: A phase I study of humanized anti-CD40 immunotherapy with SGN-40 in non-Hodgkin's lymphoma [abstract 1504]. Blood 2005, 106:433a.
31. Advani R, Forero-Torres A, Furman RR, et al.: SGN-40 (anti-huCD40 mAb) monotherapy induces durable objective responses in patients with relapsed aggressive non-Hodgkin's lymphoma: Evidence of antitumor activity from a phase I study [abstract 695]. Blood 2006, 108:209a.
32. Keating MJ, Flinn I, Jain V, et al.: Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: Results of a large international study. Blood 2002, 99:3554-3561.
33. Hillmen P, Skotnicki AB, Robak T, et al.: Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol 2007, 25:5616-5623.
34. Fanale MA, Younes A: Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma. Drugs 2007, 67:333-350.
35. Czuczman MS, Thall A, Witzig TE, et al.: Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma. J Clin Oncol 2005, 23:4390-4398.
36. Leonard JP, Friedberg JW, Younes A, et al.: A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma. Ann Oncol 2007, 18:1216-1223.
37. Friedberg JW: Developing new monoclonal antibodies for aggressive lymphoma: A challenging road in the rituximab era. Clin Cancer Res 2004, 10:5297-5298.